MDxHealth (NASDAQ:MDXH) & Geron (NASDAQ:GERN) Head-To-Head Review

MDxHealth (NASDAQ:MDXH) and Geron (NASDAQ:GERN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.

Analyst Ratings

This is a summary of current recommendations and price targets for MDxHealth and Geron, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1	4	1	0	2.00
Geron	1	2	3	0	2.33

MDxHealth currently has a consensus target price of $1.33, suggesting a potential upside of 749.26%. Geron has a consensus target price of $3.75, suggesting a potential upside of 278.86%. Given MDxHealth’s higher probable upside, research analysts clearly believe MDxHealth is more favorable than Geron.

Volatility & Risk

MDxHealth has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, Geron has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500.

Institutional and Insider Ownership

73.7% of Geron shares are held by institutional investors. 1.7% of MDxHealth shares are held by company insiders. Comparatively, 1.7% of Geron shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares MDxHealth and Geron’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MDxHealth	-33.46%	N/A	-24.25%
Geron	-23.04%	-16.29%	-6.82%

Valuation & Earnings

This table compares MDxHealth and Geron”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$107.88 million	0.07	-$33.52 million	($0.72)	-0.22
Geron	$183.88 million	3.47	-$83.50 million	($0.08)	-12.37

MDxHealth has higher earnings, but lower revenue than Geron. Geron is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Summary

Geron beats MDxHealth on 9 of the 14 factors compared between the two stocks.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.